Abstract:Background: Vγ9Vδ2 T-cells are antitumor immune effector cells that can detect metabolic dysregulation in cancer cells through phosphoantigen-induced conformational changes in the butyrophilin (BTN) 2A1/3A1 complex. In order to clinically exploit the anticancer properties of Vγ9Vδ2 T-cells, various approaches have been studied including phosphoantigen stimulation, agonistic BTN3A-specific antibodies, adoptive transfer of expanded Vγ9Vδ2 T-cells, and more recently bispecific antibodies. While Vγ9Vδ2 T-cells constitute a sizeable population, typically making up ~1-10% of the total T cell population, lower numbers have been observed with increasing age and in the context of disease. Methods: We evaluated whether bivalent single domain antibodies (VHHs) that link Vδ2-TCR specific VHHs with different affinities could support Vγ9Vδ2 T-cell expansion and could be incorporated in a bispecific engager format when additionally linked to a tumor antigen specific VHH. Results: Bivalent VHHs that link a high and low affinity Vδ2-TCR specific VHH can support Vγ9Vδ2 T-cell expansion. The majority of Vγ9Vδ2 T-cells that expanded following exposure to these bivalent VHHs had an effector or central memory phenotype and expressed relatively low levels of PD-1. Bispecific engagers that incorporated the bivalent Vδ2-TCR specific VHH as well as a tumor antigen specific VHH triggered antitumor effector functions and supported expansion of Vγ9Vδ2 T-cells in vitro and in an in vivo model in NOG-hIL-15 mice. Conclusion: By enhancing the number of Vγ9Vδ2 T-cells available to exert antitumor effector functions, these novel Vδ2-bivalent bispecific T cell engagers may promote the overall efficacy of bispecific Vγ9Vδ2 T-cell engagement, particularly in patients with relatively low levels of Vγ9Vδ2 T-cells.

Nonpeptide Antigens, Presentation Mechanisms, and Immunological Memory of Human Vγ2Vδ2 T Cells: Discriminating Friend from Foe Through the Recognition of Prenyl Pyrophosphate Antigens

Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens.

Unique features of Vγ2Vδ2 T cell memory provides for bridge immunity to infections (44.16)

Preferential Recognition of a Microbial Metabolite by Human V 2V 2 T Cells

Innate memory of human Vγ2Vδ2 T cells: Distinct proliferative, migratory and tumorcidal capabilities of γδ memory subsets (52.17)

Identification of Human T Cell Receptor Γδ-Recognized Epitopes/Proteins Via CDR3δ Peptide-based Immunobiochemical Strategy

Natural and synthetic non-peptide antigens recognized by human γδ T cells

Fast‐acting Γδ T‐cell Subpopulation and Protective Immunity Against Infections

T.137. Phosphoantigen-expanded Human Gammadelta T Cells Display Potent Cytotoxicities Towards Human and Avian Influenza Virus-infected Monocyte-derived Macrophages

Phosphoantigen recognition by Vγ9Vδ2 T cells

A blend of broadly-reactive and pathogen-selected Vγ4 Vδ1 T cell receptors confer broad bacterial reactivity of resident memory γδ T cells

Th17‐related Cytokines Contribute to Recall‐like Expansion/effector Function of HMBPP‐specific Vγ2Vδ2 T Cells after Mycobacterium Tuberculosis Infection or Vaccination

Peptide Centric Vβ Specific Germline Contacts Shape a Specialist T Cell Response

Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion

Involvement of Classical and Novel Protein Kinase C Isoforms in the Response of Human Vγ9Vδ2 T Cells to Phosphate Antigens

Phosphoantigens Glue Butyrophilin 3A1 and 2A1 to Activate Vγ9Vδ2 T Cells

Involvement of Classical and Novel Protein Kinase C Isoforms in the Response of Human Vγ9Vδ2 T Cells to Phosphate Antigens1

HMGN2: an Antitumor Effector Molecule of Γδt Cells

Hmbpp-Deficient Listeria Mutant Immunization Alters Pulmonary/Systemic Responses, Effector Functions, And Memory Polarization Of V Gamma 2v Delta 2 T Cells

Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon hepatitis B vaccination

Engineering a Dual Specificity γδ T-Cell Receptor for Cancer Immunotherapy